Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF
Jonathan W. Cunningham, Brian L. Claggett, Eileen O’Meara, Margaret F. Prescott, Marc A. Pfeffer, Sanjiv J. Shah, Margaret M. Redfield, Faiez Zannad, Lu-May Chiang, Adel R. Rizkala, Victor C. Shi, Martin P. Lefkowitz, Jean Rouleau, John J.V. McMurray, Scott D. Solomon and Michael R. Zile
Fibrosis Biomarkers in Heart Failure With Preserved Ejection Fraction
Increased hemodynamic and metabolic loads produced by the antecedent disease processes lead to the development of the clinical syndrome of heart failure with preserved ejection fraction (HFpEF). Activated fibroblasts alter both collagen synthesis and degradation; circulating biomarkers reflect these changes and are altered by treatment with sacubitril/valsartan. CITP = carboxyl-terminal telopeptide of collagen type I; PIIINP = N-terminal propeptide of collagen III; PINP = N-terminal propeptide of collagen I; sST2 = soluble ST2; TIMP = tissue inhibitor of matrix metalloproteinase.